Goldman Sachs analyst David Roman initiated coverage of Stryker with a Neutral rating and $372 price target. The firm expects Stryker to continue to execute its strategy to achieve revenue growth at the high-end of medical technology. However, its positive outlook on Stryker’s fundamentals outlook and confidence in management’s execution is balanced against a view that consensus estimates well captures the earnings trajectory of the business.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Anika enters cooperation pact with Caligan, appoints two new directors to board
- Needham medtech/diagnostic analyst holds analyst/industry conference call
- Shopify, Kraft Heinz upgraded: Wall Street’s top analyst calls
- Stryker seeing higher sales and margins, says Argus
- Stryker upgraded to Buy from Hold at Needham